Document:

<PAGE>
                                                                   Exhibit 10.13

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE SECURITIES LAWS OF ANY STATE.
THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND
MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE
APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION
THEREFROM.  THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL
(WHICH MAY BE COMPANY COUNSEL) IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER
TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT
AND ANY APPLICABLE STATE SECURITIES LAWS.

                           Warrant to Purchase Stock

Corporation:  Genomica Corporation
Number of Shares:  See Below
Class of Stock:  Series A Preferred
Initial Exercise Price:  See Below
Issue Date:  September 10, 1997
Expiration Date:  September 9, 2004

     THIS WARRANT CERTIFIES THAT, for the agreed upon value of $1.00 and for
other good and valuable consideration, SILICON VALLEY BANK ("Holder") is
entitled to purchase the number of fully paid and nonassessable shares of the
class of securities (the "Shares") of the corporation (the "Company") at the
initial exercise price per Share (the "Warrant Price") all as set forth herein
and as adjusted pursuant to Article 2 of this Warrant, subject to the provisions
and upon the terms and conditions set forth of this Warrant.  The Warrant Price
shall be equal to the price at which the Company sold its Series A Preferred
Stock pursuant to the Stock Purchase Agreement between the Company and the
Purchasers named therein; provided that the Warrant Price shall be equal to the
price per share at which the Company after the date hereof first sells its
shares of capital stock in an offering (the "Equity Event") in which the Company
receives not less than Two Million Dollars ($2,000,000) if the Company receives
the proceeds from such sale by November 30, 1997.  The number of Shares that
Holder may purchase under this Warrant is equal to Twelve Thousand Dollars
($12,000) divided by the Warrant Price; provided that, beginning September 15,
1997, and continuing on the fifteenth calendar day of each month thereafter
until Borrower receives the proceeds from the Equity Event, Holder may purchase
an additional number of Shares equal to Six Thousand Dollars ($6,000) divided by
the Warrant Price for each such month; provided the maximum number of Shares
that Holder may purchase pursuant to the terms of this sentence shall be equal
to Forty Thousand Dollars ($40,000) divided by the Warrant Price.

ARTICLE 1.  EXERCISE

            1.1  Method of Exercise.  Holder may exercise this Warrant by
delivering a duly executed Notice of Exercise in substantially the form attached
as Appendix 1 to the principal office of the Company. Unless Holder is
exercising the conversion right set forth in Section 1.2, Holder shall also
deliver to the Company a check for the aggregate Warrant Price for the Shares
being purchased.

            1.2  Conversion Right.  In lieu of exercising this Warrant as
specified in Section 1.1, Holder may from time to time convert this Warrant, in
whole or in part, into a number of Shares

                                       1.
<PAGE>

determined by dividing (a) the aggregate fair market value of the Shares or
other securities otherwise issuable upon exercise of this Warrant minus the
aggregate Warrant Price of such Shares by (b) the fair market value of one
Share. The fair market value of the Shares shall be determined pursuant Section
1.4.

            1.3  [Intentionally omitted.]

            1.4  Fair Market Value.  If the Shares are traded in a public
market, the fair market value of the Shares shall be the closing price of the
Shares (or the closing price of the Company's stock into which the Shares are
convertible) reported for the business day immediately before Holder delivers
its Notice of Exercise to the Company. If the Shares are not traded in a public
market, the Board of Directors of the Company shall determine fair market value
in its reasonable good faith judgment. The foregoing notwithstanding, if Holder
advises the Board of Directors in writing that Holder disagrees with such
determination, then the Company and Holder shall promptly agree upon a reputable
investment banking firm to undertake such valuation. If the valuation of such
investment banking firm is more than 5% greater than that determined by the
Board of Directors, then all fees and expenses of such investment banking firm
shall be paid by the Company. In all other circumstances, such fees and expenses
shall be paid by Holder.

            1.5  Delivery of Certificate and New Warrant.  Promptly after Holder
exercises or converts this Warrant, the Company shall deliver to Holder
certificates for the Shares acquired and, if this Warrant has not been fully
exercised or converted and has not expired, a new Warrant representing the
Shares not so acquired.

            1.6  Replacement of Warrants.  On receipt of evidence reasonably
satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant and, in the case of loss, theft or destruction, on delivery of an
indemnity agreement reasonably satisfactory in form and amount to the Company
or, in the case of mutilation, or surrender and cancellation of this Warrant,
the Company at its expense shall execute and deliver, in lieu of this warrant, a
new warrant of like tenor.

            1.7  Repurchase on Sale, Merger, or Consolidation of the Company.

                 1.7.1  "Acquisition".  For the purpose of this Warrant,
"Acquisition" means any sale, license, or other disposition of all or
substantially all of the assets of the Company, or any reorganization,
consolidation, or merger of the Company where the holders of the Company's
securities before the transaction beneficially own less than 50% of the
outstanding voting securities of the surviving entity after the transaction.

                 1.7.2  Assumption of Warrant.  Upon the closing of any
Acquisition the successor entity shall assume the obligations of this Warrant,
and this Warrant shall be exercisable for the same securities, cash, and
property as would be payable for the Shares issuable upon exercise of the
unexercised portion of this warrant as if such Shares were outstanding on the
record date for the Acquisition and subsequent closing. The Warrant Price shall
be adjusted accordingly.

                 1.7.3  Purchase Rights.  Notwithstanding the foregoing, at the
election of Holder, the Company shall purchase the unexercised portion of this
Warrant for cash upon the closing of any Acquisition for an amount equal to (a)
the fair market value of any consideration that would have been received by
Holder in consideration of the Shares had Holder exercised the unexercised
portion of this Warrant immediately before the record date for determining the
shareholders entitled to participate in the proceeds of the Acquisition, less
(b) the aggregate Warrant Price of the Shares, but in no event less than zero.

                                       2
<PAGE>

ARTICLE 2.  ADJUSTMENTS TO THE SHARES.

            2.1  Stock Dividends, Splits, Etc.  If the Company declares or pays
a dividend on its common stock (or the Share if the Shares are securities other
than common stock) payable in common stock, or other securities, subdivides the
outstanding common stock into a greater amount of common stock, or, if the
Shares are securities other than common stock, subdivides the Shares in a
transaction that increases the amount of common stock into which the Shares are
convertible, then upon exercise of this Warrant, for each Share acquired, Holder
shall receive, without cost to Holder, the total number and kind of securities
to which Holder would have been entitled had Holder owned the Shares of record
as of the date the dividend or subdivision occurred.

            2.2  Reclassification, Exchange or Substitution.  Upon any
reclassification, exchange, substitution, or other event that results in a
change of the number and/or class of the securities issuable upon exercise or
conversion of this Warrant, Holder shall be entitled to receive, upon exercise
or conversion of this Warrant, the number and kind of securities and property
that Holder would have received for the Shares if this Warrant had been
exercised immediately before such reclassification, exchange, substitution, or
other event. Such an event shall include any automatic conversion of the
outstanding or issuable securities of the Company of the same class or series as
the Shares to common stock pursuant to the terms of the Company's Certificate of
Incorporation upon the closing of a registered public offering of the Company's
common stock. The Company or its successor shall promptly issue to Holder a new
Warrant for such new securities or other property. The new Warrant shall provide
for adjustments which shall be as nearly equivalent as may be practicable to the
adjustments provided for in this Article 2 including, without limitation,
adjustments to the Warrant Price and to the number of securities or property
issuable upon exercise of the new Warrant. The provisions of this Section 2.2
shall similarly apply to successive reclassifications, exchanges, substitutions,
or other events.

            2.3  Adjustments for Combination, Etc.  If the outstanding Shares
are combined or consolidated, by reclassification or otherwise, into a lesser
number of shares, the Warrant Price shall be proportionately increased.

            2.4  Adjustments for Diluting Issuances.  The Warrant Price and the
number of Shares issuable upon exercise of this Warrant or, if the Shares are
Preferred Stock, the number of shares of common stock issuable upon conversion
of the Shares, shall be subject to adjustment, from time to time in accordance
with the Company's Certificate of Incorporation, as amended. In the event of the
issuance (a "Diluting Issuance") by the Company, after the Issue Date of the
Warrant, of securities at a price per share less than the Warrant Price, then
the number of shares of common stock issuable upon conversion of the Shares
shall be adjusted in accordance with those provisions (the "Provisions") of the
Company's Certificate of Incorporation which apply to Diluting Issuances. The
Company agrees that the Provisions, as in effect on the Issue Date, shall be
deemed to remain in full force and effect during the term of the Warrant at all
times prior to the sale by the Company of its equity securities in an initial
public offering, notwithstanding any subsequent amendment, waiver or termination
thereof by the Company's shareholders. Under no circumstances shall the
aggregate Warrant Price payable by the Holder upon exercise of the Warrant
increase as a result of any adjustment arising from a Diluting Issuance.

            2.5  No Impairment.  The Company shall not, by amendment of its
Certificate of Incorporation or through a reorganization, transfer of assets,
consolidation, merger, dissolution, issue, or sale of securities or any other
voluntary action, avoid or seek to avoid the observance or performance of any of
the terms to be observed or performed under this Warrant by the Company, but
shall at all times in good faith assist in carrying out of all the provisions of
this Article 2 and in taking all such action as may be necessary or appropriate
to protect Holder's rights under this Article against impairment. If the

                                       3
<PAGE>

Company takes any action affecting the Shares or its common stock other than as
described above that adversely affects Holder's rights under this Warrant, the
Warrant Price shall be adjusted downward and the number of Shares issuable upon
exercise of this Warrant shall be adjusted upward in such a manner that the
aggregate Warrant Price of this Warrant is unchanged.

            2.6  Fractional Shares.  No fractional Shares shall be issuable upon
exercise or conversion of the Warrant and the number of Shares to be issued
shall be rounded down to the nearest whole Share. If a fractional share interest
arises upon any exercise or conversion of the Warrant, the Company shall
eliminate such fractional share interest by paying Holder amount computed by
multiplying the fractional interest by the fair market value of a full Share.

            2.7  Certificate as to Adjustments.  Upon each adjustment of the
Warrant Price, the Company at its expense shall promptly compute such
adjustment, and furnish Holder with a certificate of its Chief Financial Officer
setting forth such adjustment and the facts upon which such adjustment is based.
The Company shall, upon written request, furnish Holder a certificate setting
forth the Warrant Price in effect upon the date thereof and the series of
adjustments leading to such Warrant Price.

            2.8  No Rights As Shareholders.  This Warrant does not entitle
Holder to any voting rights or other rights as a stockholder of the Company
prior to the exercise of the Holder's rights to purchase Preferred Stock as
provided for herein.

            2.9  Minimum Adjustment.  No adjustment in the Warrant Price under
this Section 2 shall be required unless such adjustment would require an
increase or decrease of at least [twenty-five cents] in such Warrant Price;
provided, however, that any adjustments which by reason of this subsection are
not required to be made, shall be carried forward and taken into account in any
subsequent adjustment. All calculations under this Section 2 shall be made to
the nearest cent or the nearest share, as the case may be.

ARTICLE 3.  REPRESENTATIONS AND COVENANTS OF THE COMPANY.

            3.1  Representations and Warranties.  The Company hereby represents
and warrants to the Holder that all Shares which may be issued upon the exercise
of the purchase right represented by this Warrant, and all securities, if any,
issuable upon conversion of the Shares, shall, upon issuance, be duly
authorized, validly issued, fully paid and nonassessable, and free of any liens
and encumbrances except for restrictions on transfer provided for herein or
under applicable federal and state securities laws.

            3.2  Notice of Certain Events.  If the Company proposes at any time
(a) to declare any dividend or distribution upon its common stock, whether in
cash, property, stock, or other securities and whether or not a regular cash
dividend; (b) to offer for subscription pro rata to the holders of any class or
series of its stock any additional shares of stock of any class of series or
other rights; (c) to effect any reclassification or recapitalization of common
stock; (d) to merge or consolidate with or into any other corporation, or sell,
lease, license, or convey all or substantially all of its assets, or to
liquidate, dissolve or wind up; or (e) offer holders of registration rights the
opportunity to participate in an underwritten public offering of the company's
securities for cash, then, in connection with each such event, the Company shall
give Holder (1) at least 20 days prior written notice of the date on which a
record will be taken for such dividend, distribution, or subscription rights
(and specifying the date on which the holders of common stock will be entitled
thereto) or for determining rights to vote, if any, in respect of the matters
referred to in (c) and (d) above; (2) in the case of the matters referred to in
(c) and (d) above at least 20 days prior written notice of the date when the
same will take place (and specifying the date on which the holders of common
stock will be entitled to exchange their common stock for securities or other
property

                                       4
<PAGE>

deliverable upon the occurrence of such event); and (3) in the case of the
matter referred to in (e) above, the same notice as is given to the holders of
such registration rights.]

            3.3  Information Rights.  So long as the Holder holds this Warrant
and/or any of the Shares, the Company shall deliver to the Holder promptly after
mailing copies of all notices or other written communications to the
shareholders of the Company, generally.

            3.4  Registration Under Securities Act of 1933, as amended.  The
Company agrees that the Shares or, if the Shares are convertible into common
stock of the Company, such common stock, shall be subject to the registration
rights set forth on Exhibit A, if attached.

ARTICLE 4.  REPRESENTATIONS AND COVENANTS OF HOLDER.

     This Warrant has been entered into the Company in reliance upon the
following representations and covenants of Holder, which by its acceptance
hereof the Holder (including any permitted transferee of Holder on behalf of
such transferee) hereby confirms:

            4.1  Investment Purpose.  The right to acquire Preferred Stock or
the Preferred Stock issuable upon exercise of Holder's rights contained herein
will be acquired for investment and not with a view to the sale or distribution
of any part thereof, and the Holder has no present intention of selling or
engaging in any public distribution of the same except pursuant to a
registration or exemption.

            4.2  Private Issue.  Holder understands (i) that the Preferred
Stock, issuable upon exercise of the Holder's rights contained herein is not
registered under the 1933 Act or qualified under applicable state securities
laws on the ground that the issuance contemplated by this Warrant Agreement will
be exempt from the registration and qualifications requirements thereof, and
(ii) that the Company's reliance on such exemption is predicated on the
representations set forth in this Section 4.

            4.3  Financial Risk.  Holder has such knowledge and experience in
financial and business matters as to be capable of evaluating the merits and
risks of its investment and has the ability to bear the economic risks of its
investments.

            4.4  Risk of No Registration.  Holder understands that if the
Company does not register with the Securities and Exchange commission pursuant
to Section 12 of the 1933 Act, or file reports pursuant to Section 15(d) of the
Securities Exchange Act of 1934 (the "1934 Act"), or if a registration statement
covering the securities under the 1933 Act is not in effect when it desires to
sell (i) the rights to purchase Preferred Stock pursuant to this Warrant
Agreement, or (ii) the Preferred Stock issuable upon exercise of the right to
purchase, it may be required to hold such securities for an indefinite period.
The Holder also understands that any sale of the rights of the Holder to
purchase Preferred Stock which might be made by it in reliance upon Rule 144
under the 1933 Act may be made only in accordance with the terms and conditions
of that Rule.

            4.5  Accredited Investor.  Holder is an "accredited investor" within
the meaning of Rule 501 of Regulation D under the Act, as presently in effect.

ARTICLE 5.  MISCELLANEOUS.

            5.1  Term:  Notice of Expiration.  This Warrant is exercisable, in
whole or in part, at any time and from time to time on or before the Expiration
Date set forth above. To the extent this Warrant is not previously exercised,
and if the fair market value of one Share is greater than the Warrant

                                       5
<PAGE>

Price then in effect, this Warrant shall be deemed automatically exercised
pursuant to Section 1.2 above immediately before its expiration. For purposes of
such automatic exercise, the fair market value of one Share upon expiration
shall be determined pursuant to Section 1.3 above.

            5.2  Legends.  This Warrant and the Shares (and the securities
issuable, directly or indirectly, upon conversion of the Shares, if any) shall
be imprinted with a legend in substantially the following form:

     THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
     SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE SECURITIES
     LAWS OF ANY STATE.  THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON
     TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS
     PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT
     TO REGISTRATION OR EXEMPTION THEREFROM.  THE ISSUER OF THESE SECURITIES MAY
     REQUIRE AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) IN FORM AND
     SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED
     TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE
     SECURITIES LAWS.

            5.3  Compliance with Securities Laws on Transfer.  This Warrant and
the Shares issuable upon exercise this Warrant (and the securities issuable,
directly or indirectly, upon conversion of the Shares, if any) may not be
transferred or assigned in whole or in part without compliance with applicable
federal and state securities laws by the transferor and the transferee
(including, without limitation, the delivery of investment representation
letters and legal opinions reasonably satisfactory to the Company, as reasonably
requested by the Company). The Company shall not require Holder to provide an
opinion of counsel if the transfer is to an affiliate of Holder or if there is
no material questions as to the availability of current information as
referenced in Rule 144(c), Holder represents that it has complied with Rule
144(d) and (e) in reasonable detail, the selling broker represents that it has
complied with Rule 144(f), and the Company is provided with a copy of Holder's
notice of proposed sale.

            5.4  Transfer Procedure.  Subject to the provisions of Section 5.3,
Holder may transfer all or part of this Warrant or the Shares issuable upon
exercise of this Warrant (or the securities issuable, directly or indirectly,
upon conversion of the Shares, if any) by giving the Company notice of the
portion of the Warrant being transferred setting forth the name, address and
taxpayer identification number of the transferee and surrendering this Warrant
to the Company for reissuance to the transferee(s) (and Holder if applicable).
Unless the Company is filing financial information with the SEC pursuant to the
Securities Exchange Act of 1934, the Company shall have the right to refuse to
transfer any portion of this Warrant to any person who directly competes with
the Company.

            5.5  Notices.  All notices and other communications from the Company
to the Holder, or vice versa, shall be deemed delivered and effective when given
personally or mailed by first-class registered or certified mail, postage
prepaid, at such address as may have been furnished to the Company or the
Holder, as the case may be, in writing by the Company or such holder from time
to time.

            5.6  Waiver.  This Warrant and any term hereof may be changed,
waived, discharged or terminated only by an instrument in writing signed by the
party against which enforcement of such change, waiver, discharge or termination
is sought.

                                       6
<PAGE>

            5.7  Attorneys Fees.  In the event of any dispute between the
parties concerning the terms and provisions of this Warrant, the party
prevailing in such dispute shall be entitled to collect from the other party all
costs incurred in such dispute, including reasonable attorneys' fees.

            5.8  Governing Law.  This Warrant shall be governed by and
constructed in accordance with the laws of the State of California, without
giving effect to its principles regarding conflicts of law.

                                       GENOMICA CORPORATION,
                                       a Delaware corporation

                                       By: /s/ Thomas G. Marr
                                           -------------------------------------

                                       Name:   Thomas G. Marr
                                             -----------------------------------
                                                            (Print)

                                       Title:  Chairman of the Board, President,
                                               or Vice President

                                       By: /s/ Kenneth J. Collins
                                           -------------------------------------

                                       Name:   Kenneth J. Collins, CFO
                                             -----------------------------------
                                                            (Print)

                                       Title:  Chief Financial Officer,
                                               Secretary Assistant Treasurer, or
                                               Assistant Secretary

                                       7
<PAGE>

                                   EXHIBIT A
                                   ---------

                           Investor Rights Agreement
                           -------------------------

     The Company agrees that no amendments will be made to the Agreement which
would treat the Holder in a manner differently than the other holders of like
securities of the Company without the consent of Holder.

     The Company agrees, and by acceptance of the Warrant to which this Exhibit
A is attached Holder agrees, that at such time this Warrant is exercised, Holder
shall become a party to the Registration Rights Agreement dated as of March 22,
1996 by and among the Company and certain of the Company's stockholders (as
amended, modified, supplemented or restated, the "Registration Rights
Agreement"), shall be treated as a "Purchaser" of "Preferred Shares" thereunder,
shall have the rights, privileges and responsibilities of a party thereto, and
agrees to execute counterpart signature pages thereto at the request of the
Company.

                                       8.
<PAGE>

                                  APPENDIX 1

                              NOTICE OF EXERCISE
                              ------------------

     1.  The undersigned hereby elects to purchase ________ shares of the Series
__ Preferred Stock of Genomica Corporation pursuant to the terms of the attached
Warrant, and tenders herewith payment of the purchase price of such shares in
full.

     1.  The undersigned hereby elects to convert the attached Warrant into
Shares/cash [strike one] in the manner specified in the Warrant. This conversion
is exercised with respect to __________________ of the Shares covered by the
Warrants.

     [Strike paragraph that does not apply.]

     2.  Please issue a certificate or certificates representing said shares in
the name of the undersigned or in such other name as is specified below:

                           _________________________
                                    (Name)

                           _________________________

                           _________________________
                                   (Address)

     3.  The undersigned represents it is acquiring the shares solely for its
own account and not as a nominee for any other party and not with a view toward
the resale or distribution thereof except in compliance with applicable
securities laws.

                                       _________________________________________
                                       (Signature)

_________________________
         (Date)

                                       9.<PAGE>
                                                                   Exhibit 10.14

                                                              Warrant No. WP__5

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT
AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR ANY STATE
SECURITIES LAWS.  SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE
OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SAID ACT AND ANY APPLICABLE
STATE SECURITIES LAWS.

                              WARRANT TO PURCHASE

                         SHARES OF PREFERRED STOCK OF
                             GENOMICA CORPORATION
          (Void after the date that is 5 years after the date hereof)

     This certifies that [    ] (the "Holder"), or assigns, for value received,
is entitled to purchase from Genomica Corporation, a Delaware corporation (the
"Company"), having a place of business at 4001 Discovery Drive, Suite 130,
Boulder, Colorado 80303, a number of fully paid and non-assessable shares of the
Company's Applicable Series Preferred (as defined below) up to the Coverage
Amount (as defined below), and any security into or for which such Applicable
Series Preferred may hereafter be converted or exchanged pursuant to the
Certificate of Incorporation of the Company as from time to time amended as
provided by law, for cash at a price per share equal to the price per share (the
"Stock Purchase Price") at which the next round of Preferred Stock issued and
sold by the Company in which the gross proceeds to the Borrower are at least
$3,000,000, not including the conversion of any Notes (such an issuance and
sale, a "Qualified Financing"), at any time on or after the date that the
Applicable Series Preferred is first issued and sold or from time to time up to
and including 5:00 p.m. (Mountain Time) on, until the date 5 years after the
date of such Qualified Financing, such day being referred to herein as the
"Expiration Date," upon surrender to the Company at its principal office (or at
such other location as the Company may advise the Holder in writing) of this
Warrant properly endorsed with the Subscription Form attached hereto as Exhibit
A and the Investment Representations Letter attached hereto as Exhibit B duly
filled in and signed and, if applicable, upon payment in cash or by check of the
aggregate Stock Purchase Price for the number of shares for which this Warrant
is being exercised determined in accordance with the provisions hereof. The
"Applicable Series Preferred" shall be the series of Preferred Stock next issued
and sold by the Company in a Qualified Financing. The "Coverage Amount" shall
equal a number of shares computed as follows:

          (the principal amount of the Convertible Promissory Note(s)
         issued by the Company x 15% to the Holder on the date hereof)

       ----------------------------------------------------------------
                             Stock Purchase Price

     The Stock Purchase Price and the number of shares purchasable hereunder are
subject to adjustment as provided in Section 3 of this Warrant.

                                       1.
<PAGE>

     1.   Exercise; Issuance of Certificates; Payment for Shares.

          1.1  General.  This Warrant is exercisable at the option of the Holder
of record hereof, at any time or from time to time, commencing on the date
hereof up to the Expiration Date for all or any part of the shares of Applicable
Series Preferred (but not for a fraction of a share) which may be purchased
hereunder.

          1.2  Issuance of Certificates.  The Company agrees that the shares of
Applicable Series Preferred purchased under this Warrant shall be and are deemed
to be issued to the Holder hereof as the record owner of such shares as of the
close of business on the date on which this Warrant shall have been surrendered,
properly endorsed, the completed, executed Subscription Form (a copy of which is
attached hereto as Exhibit A) and Investment Representations Letter (a copy of
which is attached hereto as Exhibit B) delivered and payment (if any) made for
such shares.  Certificates for the shares of Applicable Series Preferred so
purchased, together with any other securities or property to which the Holder
hereof is entitled upon such exercise, shall be delivered to the Holder hereof
by the Company at the Company's expense promptly after the rights represented by
this Warrant have been so exercised.  Each stock certificate so delivered shall
be in such denominations of Applicable Series Preferred as may be requested by
the Holder hereof and shall be registered in the name of such Holder.  In case
of a purchase of less than all the shares which may be purchased under this
Warrant, the Company shall cancel this Warrant and execute and deliver a new
Warrant or Warrants of like tenor for the balance of the shares purchasable
under the Warrant surrendered upon such purchase to the Holder hereof within a
reasonable time.

          1.3  Net Issue Exercise.  Notwithstanding any provisions herein to the
contrary, if the fair market value of one share of the Company's Applicable
Series Preferred is greater than the Stock Purchase Price (at the date of
calculation as set forth below), in lieu of exercising this Warrant for cash,
the Holder may elect to receive shares equal to the value (as determined below)
of this Warrant (or the portion thereof being canceled) by surrender of this
Warrant at the principal office of the Company together with the properly
endorsed Form of Subscription and notice of such election in which event the
Company shall issue to the Holder a number of shares of Applicable Series
Preferred computed using the following formula:

          X = Y (A-B)
              -------
                A

Where     X =   the number of shares of Applicable Series Preferred to be issued
                to the Holder

          Y =   the number of shares of Applicable Series Preferred purchasable
                under the Warrant or, if only a portion of the Warrant is being
                exercised, the portion of the Warrant being canceled (at the
                date of such calculation)

          A =   the fair market value of one share of the Company's Applicable
                Series Preferred (at the date of such calculation)

                                       2.
<PAGE>

          B =   Stock Purchase Price (as adjusted to the date of such
                calculation)

For purposes of the above calculation, the fair market value of one share of
Applicable Series Preferred shall be determined by the Company's Board of
Directors in good faith; provided, however, that in the event the Company makes
an initial public offering of its Common Stock the fair market value per share
shall be: (i) if the Warrant is being converted in connection with and
contingent upon a public offering of the Company's securities, and if the
Company's registration statement relating to such public offering has been
declared effective by the U.S. Securities and Exchange Commission, then the fair
market value of the Applicable Series Preferred shall be the initial "Price to
Public" specified in the final prospectus with respect to such offering
multiplied by the number of shares of Common Stock into which each share of
Applicable Series Preferred is then convertible; or (ii) if the Warrant is not
being converted in connection with and contingent upon a public offering of the
Company's securities, then as follows: (x) if traded on a securities exchange,
the Nasdaq National Market or the Nasdaq SmallCap Market, the fair market value
of the Common Stock shall be deemed to be the average of the closing or last
reported sale prices of the Common Stock on such exchange or market over the 30-
day period ending five business days prior to the date of calculation, and the
fair market value of the Applicable Series Preferred shall be deemed to be such
fair market value of the Common Stock multiplied by the number of shares of
Common Stock into which each share of Applicable Series Preferred is then
convertible or (y) if otherwise traded in an over-the-counter market, the fair
market value of the Common Stock shall be deemed to be the median of the average
of the reported closing bid and ask prices of the Common Stock over the 30-day
period ending five business days prior to the date of calculation, and the fair
market value of the Applicable Series Preferred shall be deemed to be such fair
market value of the Common Stock multiplied by the number of shares of Common
Stock into which each share of Applicable Series Preferred is then convertible.

     2.   Shares to be Fully Paid; Reservation of Shares.  The Company covenants
and agrees that all shares of Applicable Series Preferred that may be issued
upon the exercise of the rights represented by this Warrant will, upon issuance,
be duly authorized, validly issued, fully paid and non-assessable and free from
all preemptive rights of any stockholder and free of all taxes, liens and
charges with respect to the issue thereof.  The Company further covenants and
agrees that, during the period within which the rights represented by this
Warrant may be exercised, the Company will at all times have authorized and
reserved, for the purpose of issue or transfer upon exercise of the subscription
rights evidenced by this Warrant, a sufficient number of shares of authorized
but unissued Applicable Series Preferred, or other securities and property, when
and as required to provide for the exercise of the rights represented by this
Warrant.  The Company will take all such action as may be necessary to assure
that such shares of Applicable Series Preferred may be issued as provided herein
without violation of any applicable law or regulation, or of any requirements of
any domestic securities exchange upon which the Applicable Series Preferred may
be listed; provided, however, that the Company shall not be required to effect a
registration under federal or state securities laws with respect to such
exercise.  The Company will not take any action which would result in any
adjustment of the Stock Purchase Price (as set forth in Section 3 hereof) (i) if
the total number of shares of Applicable Series Preferred issuable after such
action upon exercise of all outstanding warrants and options, together with all
shares of Applicable Series Preferred then outstanding and all

                                       3.
<PAGE>

shares of Applicable Series Preferred then issuable upon the conversion of all
convertible securities then outstanding, would exceed the total number of shares
of Applicable Series Preferred then authorized by the Company's Certificate of
Incorporation, or (ii) if the total number of shares of Common Stock issuable
after such action upon the conversion of all outstanding shares of Applicable
Series Preferred, together with all shares of Common Stock then issuable upon
the conversion of all shares of Applicable Series Preferred then issuable upon
exercise of all outstanding warrants and options, together with all shares of
Common Stock then outstanding and all shares of Common Stock then issuable upon
exercise of all warrants and options and upon the conversion of all convertible
securities then outstanding would exceed the total number of shares of Common
Stock then authorized by the Company's Certificate of Incorporation.

     3.   Adjustment of Stock Purchase Price and Number of Shares.  The Stock
Purchase Price and the number of shares purchasable upon the exercise of this
Warrant shall be subject to adjustment from time to time upon the occurrence of
certain events described in this Section 3.  Upon each adjustment of the Stock
Purchase Price, the Holder of this Warrant shall thereafter be entitled to
purchase, at the Stock Purchase Price resulting from such adjustment, the number
of shares obtained by multiplying the Stock Purchase Price in effect immediately
prior to such adjustment by the number of shares purchasable pursuant hereto
immediately prior to such adjustment, and dividing the product thereof by the
Stock Purchase Price resulting from such adjustment.

          3.1  Subdivision of Combination of Stock.  In case the Company shall
at any time subdivide its outstanding shares of Applicable Series Preferred into
a greater number of shares, the Stock Purchase Price in effect immediately prior
to such subdivision shall be proportionately reduced, and conversely, in case
the outstanding shares of Applicable Series Preferred of the Company shall be
combined into a smaller number of shares, the Stock Purchase Price in effect
immediately prior to such combination shall be proportionately increased.

          3.2  Dividends in Common Stock, Other Stock, Property,
Reclassification.  If at any time or from time to time the holders of Applicable
Series Preferred (or any shares of stock or other securities at the time
receivable upon the exercise of this Warrant) shall have received or become
entitled to receive, without payment therefor,

               3.2.1  Applicable Series Preferred or any shares of stock or
other securities which are at any time directly or indirectly convertible into
or exchangeable for Applicable Series Preferred, or any rights or options to
subscribe for, purchase or otherwise acquire any of the foregoing by way of
dividend or other distribution;

               3.2.2  Any cash paid or payable otherwise than as a cash
dividend; or

               3.2.3  Applicable Series Preferred or additional stock or other
securities or property (including cash) by way of spin-off, split-up,
reclassification, combination of shares or similar corporate rearrangement
(other than (i) shares of Applicable Series Preferred issued as a stock split,
adjustments in respect of which shall be covered by the terms of Section 3.1
above or (ii) an event for which adjustment is otherwise made pursuant to
Section 3.3 below);

                                       4.
<PAGE>

then and in each such case, the Holder hereof shall, upon the exercise of this
Warrant, be entitled to receive, in addition to the number of shares of
Applicable Series Preferred receivable thereupon, and without payment of any
additional consideration therefor, the amount of stock and other securities and
property (including cash in the cases referred to in clauses 3.2.2 and 3.2.3
above) which such Holder would hold on the date of such exercise had he been the
Holder of record of such Applicable Series Preferred as of the date on which
holders of Applicable Series Preferred received or became entitled to receive
such shares or all other additional stock and other securities and property.

          3.3  Reorganization, Reclassification, Consolidation, Merger or Sale.

               3.3.1   If any recapitalization, reclassification or capital
reorganization of the capital stock of the Company (including any merger not
described in Section 3.3.2 below) shall be effected in such a way that holders
of Applicable Series Preferred shall be entitled to receive stock, securities,
or other assets or property (a "Restructuring"), then, as a condition of such
Restructuring, lawful and adequate provisions shall be made whereby the Holder
hereof shall thereafter have the right to purchase and receive (in lieu of the
shares of the Applicable Series Preferred of the Company immediately theretofore
purchasable and receivable upon the exercise of the rights represented hereby)
such shares of stock, securities or other assets or property as may be issued or
payable with respect to or in exchange for a number of outstanding shares of
such Applicable Series Preferred equal to the number of shares of such stock
immediately theretofore purchasable and receivable upon the exercise of the
rights represented hereby. In any Restructuring described above, appropriate
provision shall be made with respect to the rights and interests of the Holder
of this Warrant to the end that the provisions hereof (including, without
limitation, provisions for adjustments of the Stock Purchase Price and of the
number of shares purchasable and receivable upon the exercise of this Warrant)
shall thereafter be applicable, as nearly as may be, in relation to any shares
of stock, securities or assets thereafter deliverable upon the exercise hereof.

               3.3.2   In the event of a consolidation or merger of the Company
with another corporation in which the holders of the Company's voting securities
before the transaction beneficially own less than 50% of the voting securities
of the surviving entity after the transaction, or the sale of all or
substantially all of its assets of the Company (a "Change of Control"), any
unexercised portion of this Warrant shall be deemed to have been automatically
converted pursuant to Section 1.3 hereof and thereafter the Holder shall
participate in the Change of Control on the same terms as other holders of the
Applicable Series Preferred; provided however, that if the Stock Purchase Price
in effect immediately prior to the Change of Control exceeds the value of the
stock, securities or other assets or property (determined in good faith by the
Board of Directors of the Company) issuable or payable with respect to one share
of Applicable Series Preferred immediately theretofore purchasable and
receivable upon exercise of the rights represented hereby, the Warrant shall
terminate and be of no further effect as of the Change of Control.

          3.4  Notice of Adjustment.  Upon any adjustment of the Stock Purchase
Price or any increase or decrease in the number of shares purchasable upon the
exercise of this Warrant, the Company shall give written notice thereof, by
certified mail, postage prepaid, or by

                                       5.
<PAGE>

reputable overnight courier, addressed to the registered Holder of this Warrant
at the address of such Holder as shown on the books of the Company. The notice
shall be signed by an officer of the Company and shall state the Stock Purchase
Price resulting from such adjustment and the increase or decrease, if any, in
the number of shares purchasable at such price upon the exercise of this
Warrant, setting forth in reasonable detail the method of calculation and the
facts upon which such calculation is based.

          3.5  Other Notices.  If at any time:

               3.5.1  the Company shall declare any cash dividend upon its
Applicable Series Preferred;

               3.5.2  the Company shall declare any dividend upon its Applicable
Series Preferred payable in stock or make any special dividend or other
distribution to the holders of its Applicable Series Preferred;

               3.5.3  there shall be any Restructuring or Change of Control;

               3.5.4  there shall be a voluntary or involuntary dissolution,
liquidation or winding-up of the Company; or

               3.5.5  there shall be an initial public offering of securities of
the Company;

     then, in any one or more of said cases, the Company shall give, by
certified mail, postage prepaid, or by reputable overnight courier, addressed to
the Holder of this Warrant at the address of such Holder as shown on the books
of the Company, (a) at least twenty (20) days prior written notice of the date
on which the books of the Company shall close or a record shall be taken for
such dividend, distribution or subscription rights or for determining rights to
vote in respect of any such Restructuring, Change of Control, dissolution,
liquidation or winding-up, and (b) in the case of any such Restructuring, Change
of Control, dissolution, liquidation, winding-up or public offering, at least
twenty (20) days prior written notice of the date when the same shall take
place; provided, however, that the Holder shall make a best efforts attempt to
respond to such notice as early as possible after the receipt thereof.  Any
notice given in accordance with the foregoing clause (a) shall also specify, in
the case of any such dividend, distribution or subscription rights, the date on
which the holders of Applicable Series Preferred shall be entitled thereto.  Any
notice given in accordance with the foregoing clause (b) shall also specify the
date on which the holders of Applicable Series Preferred shall be entitled to
exchange their Applicable Series Preferred for securities or other property
deliverable upon such Restructuring, Change of Control, dissolution,
liquidation, winding-up or public offering, as the case may be.

          3.6  Certain Events.  If any change in the outstanding Applicable
Series Preferred of the Company or any other event occurs as to which the other
provisions of this Section 3 are not strictly applicable or if strictly
applicable would not fairly protect the purchase rights of the Holder of the
Warrant in accordance with such provisions, the Board of Directors of the
Company shall make an adjustment in the number and class of shares available
under the

                                       6.
<PAGE>

Warrant, the Stock Purchase Price or the application of such provisions, so as
to protect such purchase rights as aforesaid. The adjustment shall be such as
will give the Holder of the Warrant upon exercise for the same aggregate Stock
Purchase Price the total number, class and kind of shares as he would have owned
had the Warrant been exercised prior to the event and had he continued to hold
such shares until after the event requiring adjustment.

     4.   Issue Tax.  The issuance of certificates for shares of Applicable
Series Preferred upon the exercise of the Warrant shall be made without charge
to the Holder of the Warrant for any issue tax in respect thereof; provided,
however, that the Company shall not be required to pay any tax which may be
payable in respect of any transfer involved in the issuance and delivery of any
certificate in a name other than that of the then Holder of the Warrant being
exercised.

     5.   Closing of Books.  The Company will at no time close its transfer
books against the transfer of any warrant or of any shares of Applicable Series
Preferred issued or issuable upon the exercise of any warrant in any manner
which interferes with the timely exercise of this Warrant.

     6.   No Voting or Dividend Rights; Limitation of Liability.  Nothing
contained in this Warrant shall be construed as conferring upon the Holder
hereof the right to vote or to consent or to receive notice as a stockholder of
the Company or any other matters or any rights whatsoever as a stockholder of
the Company.  Except as provided herein, no dividends or interest shall be
payable or accrued in respect of this Warrant or the interest represented hereby
or the shares purchasable hereunder until, and only to the extent that, this
Warrant shall have been exercised.  No provision hereof in the absence of
affirmative action by the Holder to purchase shares of Applicable Series
Preferred, and no mere enumeration herein of the rights or privileges of the
Holder hereof, shall give rise to any liability of such Holder for the Stock
Purchase Price or as a stockholder of the Company, whether such liability is
asserted by the Company or by its creditors.

     7.   Warrants Transferable.  Subject to compliance with applicable federal
and state securities laws, this Warrant and all rights hereunder are
transferable, in whole or in part, without charge to the Holder hereof (except
for transfer taxes), upon surrender of this Warrant properly endorsed and in
compliance with such provisions.  Each taker and Holder of this Warrant, by
taking or holding the same, consents and agrees that this Warrant, when endorsed
in blank, shall be deemed negotiable, and that the transferee, when this Warrant
shall have been so endorsed, may be treated by the Company, at the Company's
option, and all other persons dealing with this Warrant as the absolute owner
hereof for any purpose and as the person entitled to exercise the rights
represented by this Warrant, or to the transfer hereof on the books of the
Company, any notice to the contrary notwithstanding; but until such transfer on
such books, the Company may treat the registered owner hereof as the owner for
all purposes.  Upon any such transfer, all references in this Warrant to the
"Holder" shall be deemed to refer to the transferee of this Warrant.

                                       7.
<PAGE>

     8.   Modification and Waiver.  Any change, waiver, discharge or termination
agreed to in writing by a majority in interest of Holders of Warrants of the
Company of even date (determined by reference to the number of shares underlying
such Warrants) shall be binding on the Holder and the Holder's assigns.

     9.   Notices.  Any notice, request or other document required or permitted
to be given or delivered to the Holder hereof or the Company shall be delivered
or shall be sent by certified mail, postage prepaid, to each such Holder at its
address as shown on the books of the Company or to the Company at the address
indicated therefor in the first paragraph of this Warrant or such other address
as either may from time to time provide to the other and shall be deemed to be
received upon delivery or four (4) business days after deposit in the U.S. mail.

     10.  Descriptive Headings and Governing Law.  The description headings of
the several sections and paragraphs of this Warrant are inserted for convenience
only and do not constitute a part of this Warrant.  This Warrant shall be
construed and enforced in accordance with, and the rights of the parties shall
be governed by, the laws of the State of Colorado.

     11.  Lost Warrants.  The Company represents and warrants to the Holder
hereof that upon receipt of evidence reasonably satisfactory to the Company of
the loss, theft, destruction, or mutilation of this Warrant and, in the case of
any such loss, theft or destruction, upon receipt of an indemnity reasonably
satisfactory to the Company, or in the case of any such mutilation upon
surrender and cancellation of such Warrant, the Company, at its expense, will
make and deliver a new Warrant, of like tenor, in lieu of the lost, stolen,
destroyed or mutilated Warrant.

     12.  Fractional Shares.  No fractional shares shall be issued upon exercise
of this Warrant.  The Company shall, in lieu of issuing any fractional share,
pay the Holder entitled to such fraction a sum in cash equal to such fraction
multiplied by the then effective Stock Purchase Price.

     13.  Binding Effect on Successors.  This Warrant shall be binding upon any
corporation succeeding the Company by merger, consolidation or acquisition of
all or substantially all of the Company's assets.  All of the obligations of the
Company relating to the Applicable Series Preferred issuable upon the exercise
of this Warrant shall survive the exercise and termination of this Warrant.  All
of the covenants and agreements of the Company shall inure to the benefit of the
successors and assigns of the holder hereof.

     14.  Rights of Applicable Series Preferred.  Upon the exercise of this
Warrant into shares of Applicable Series Preferred, the Company shall grant, and
ensure that the Holder is given, identical rights with respect to such shares of
Applicable Series Preferred as those granted to the holders of the then
outstanding Applicable Series Preferred who hold like amounts of Applicable
Preferred Stock.  For purposes of this Section, all shares of Applicable Series
Preferred owned by Holder shall be aggregated.

                                       8.
<PAGE>

     In Witness Whereof, the Company has caused this Warrant to be duly executed
by its President, thereunto duly authorized this 9th day of October, 1998.

                                        Genomica Corporation,
                                        a Delaware corporation

                                        /s/ Thomas G. Marr
                                        ---------------------------------
                                        Thomas G. Marr
                                        President

                                       9.
<PAGE>

                                   Exhibit A

                               SUBSCRIPTION FORM

                                                      Date:______________, 19___

Genomica Corporation
4001 Discovery Drive
Suite 130
Boulder, CO 80303
Attn: President

Ladies and Gentlemen:

[_]  The undersigned hereby elects to exercise the warrant issued to it by
     Genomica Corporation (the "Company") and dated ____________________, 1998,
     Warrant No. WP-__ (the "Warrant") and to purchase thereunder __________
     shares of the Applicable Series Preferred (as defined in the Warrant) of
     the Company (the "Shares") at a purchase price of the Applicable Series
     Preferred Price per Share, or an aggregate purchase price of
     ___________________________________ ($__________) (the "Purchase Price").

[_]  The undersigned hereby elects to convert ___________________ percent (___%)
     of the value of the Warrant pursuant to the provisions of Section 1.3 of
     the Warrant.

     Pursuant to the terms of the Warrant the undersigned has delivered the
Purchase Price herewith in full in cash or by certified check or wire transfer
or under the net exercise provision.  The undersigned also makes the
representations set forth on the attached Exhibit B of the Warrant.

                                        Very truly yours,

                                        _________________________________

                                        By:______________________________

                                        Title:___________________________
<PAGE>

                                   Exhibit B

                           INVESTMENT REPRESENTATIONS

THIS AGREEMENT MUST BE COMPLETED, SIGNED AND RETURNED TO GENOMICA CORPORATION
ALONG WITH THE SUBSCRIPTION FORM BEFORE THE APPLICABLE SERIES PREFERRED ISSUABLE
UPON EXERCISE OF THE WARRANT DATED OCTOBER 9, 1998, WILL BE ISSUED.

                                                     _____________________, 19__

Genomica Corporation
4001 Discovery Drive
Suite 130
Boulder, Colorado 80303
Attn: President and Chief Executive Officer

Ladies and Gentlemen:

     The undersigned, _______________________ ("Purchaser"), intends to acquire
up to __________________ shares of the Applicable Series Preferred (as defined
in the Warrant to purchase such Applicable Series Preferred held by the
Purchaser (the "Warrant")) of Genomica Corporation (the "Company") from the
Company pursuant to the exercise or conversion of the Warrant. The Applicable
Series Preferred will be issued to Purchaser in a transaction not involving a
public offering and pursuant to an exemption from registration under the
Securities Act of 1933, as amended (the "1933 Act") and applicable state
securities laws. Purchaser has been advised that the Applicable Series Preferred
has not been registered under the 1933 Act or state securities laws on the
ground that this transaction is exempt from registration, and that reliance by
the Company on such exemptions is predicated in part on Purchaser's
representations set forth in this letter. Accordingly, Purchaser represents,
warrants and agrees as follows:

     1.   Purchaser is acquiring the Applicable Series Preferred for its own
account and beneficial interest, to hold for investment and not for sale or with
a view to distribution of the Applicable Series Preferred or any part thereof.
Purchaser has no present intention of selling (in connection with a distribution
or otherwise), granting any participation in, or otherwise distributing the
same, and does not presently have reason to anticipate a change in such
intention.

     2.   Purchaser acknowledges that it has received all the information it has
requested from the Company and considers necessary or appropriate for deciding
whether to acquire the Applicable Series Preferred.  Purchaser represents that
it has had an opportunity to ask questions and receive answers from the Company
regarding the terms and conditions of the offering of the Applicable Series
Preferred and to obtain any additional information necessary to verify the
accuracy of the information given the Purchaser.  Purchaser further represents
that it has such knowledge and experience in financial and business matters that
it is capable of evaluating the merits and risk of this investment.
<PAGE>

     3.   Purchaser is an "accredited investor" as such term is defined in Rule
501 under the 1933 Act.

     4.   Purchaser acknowledges that investment in the Applicable Series
Preferred involves a high degree of risk, and represents that it is able,
without materially impairing its financial condition, to hold the Applicable
Series Preferred for an indefinite period of time and to suffer a complete loss
of its investment.

     5.   Purchaser has been informed that under the 1933 Act, the Applicable
Series Preferred must be held indefinitely unless it is subsequently registered
under the 1933 Act or unless an exemption from such registration (such as Rule
144) is available with respect to any proposed transfer or disposition by
Purchaser of the Applicable Series Preferred. Purchaser further agrees that the
Company may refuse to permit Purchaser to sell, transfer or dispose of the
Applicable Series Preferred (except as permitted under Rule 144) unless there is
in effect a registration statement under the 1933 Act and any applicable state
securities laws covering such transfer, or unless, if reasonably required,
Purchaser furnishes an opinion of counsel reasonably satisfactory to counsel for
the Company, to the effect that such registration is not required. Purchaser
shall not make any sale, transfer or other disposition of the Applicable Series
Preferred in violation of the 1933 Act or the General Rules and Regulations
promulgated thereunder by the Securities and Exchange Commission or in violation
of any applicable state securities law.

     6.   Purchaser also understands and agrees that there will be placed on the
certificate(s) for the Applicable Series Preferred, or any substitutions
therefor, a legend stating in substance:

     "The shares represented by this certificate have not been registered
     under the Securities Act of 1933, as amended (the "1933 Act"), or
     any state securities laws. These shares have been acquired for
     investment and may not be sold or otherwise transferred in the
     absence of an effective registration statement for these shares
     under the 1933 Act and applicable state securities laws, or, if
     reasonably required, an opinion of counsel satisfactory to the
     Company that registration is not required and that an applicable
     exemption is available."

     Purchaser has carefully read this letter and has discussed its requirements
and other applicable limitations upon Purchaser's resale of the Applicable
Series Preferred with Purchaser's counsel.

                                        Very truly yours,

                                        __________________________________

                                        By:_______________________________

                                        Title:____________________________
<PAGE>

                 Warrant Agreements - Series B Preferred Stock
                 ---------------------------------------------

                             Supplemental Schedule
                             ---------------------

The following investors executed Warrant Agreements to purchase Series B
Preferred Stock:

Investor                                      Number of Shares
--------                                      ----------------

Invesco Global Health Sciences Fund           75,520

Falcon Technology Partners, L.P.              75,520

ARCH Ventures Fund III, L.P.                  49,479

Boulder Ventures, L.P.                        5,208

The Caruthers Family L.L.C                    2,604

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}]]